Merck & Co., Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (Deprecated 2012-01-31)
Merck & Co., Inc. (MRK) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (Deprecated 2012-01-31) of $38.63 as of 2012-03-31, per its 10-Q filed 2012-05-08.
Discontinued › Notes › Compensation Related Costs
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2012-05-08
- 2012-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (Deprecated 2012-01-31) $38.63.
- 2011-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (Deprecated 2012-01-31) $36.47.
- 2011-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (Deprecated 2012-01-31) $36.55.
- 2011-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (Deprecated 2012-01-31) $36.55.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (Deprecated 2012-01-31) |
|---|---|
| 2012-03-31 | $38.63 10-Q · filed 2012-05-08 |
| 2011-12-31 | $36.47 10-K · filed 2012-02-28 |
| 2011-09-30 | $36.55 10-Q · filed 2011-11-08 |
| 2011-06-30 | $36.55 10-Q · filed 2011-08-08 |
| 2011-03-31 | $33.27 10-Q · filed 2012-05-08 |
| 2010-12-31 | $34.30 10-K · filed 2012-02-28 |
| 2010-09-30 | $34.27 10-Q · filed 2011-11-08 |
| 2010-06-30 | $34.25 10-Q · filed 2011-08-08 |
| 2010-03-31 | $37.49 10-Q · filed 2011-05-09 |
| 2009-12-31 | $24.31 10-K · filed 2012-02-28 |
| 2008-12-31 | $43.35 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |